Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Integral Diagnostics Ltd. ( (AU:IDX) ) has shared an announcement.
Integral Diagnostics Limited has disclosed a change in director James Tobias Hall’s relevant interest in the company’s shares, following an on-market purchase. Hall, via the JTH & FMD SMSF account in which he is a director, shareholder of the trustee and beneficiary, acquired 6,200 fully paid ordinary shares at $2.43 per share on 31 December 2025, increasing his indirect holding from 194,292 to 200,492 shares. The transaction did not involve any disposals, no related contracts were affected, and the trade did not occur during a closed period, signalling a routine portfolio adjustment rather than a governance or compliance event.
The most recent analyst rating on (AU:IDX) stock is a Sell with a A$2.10 price target. To see the full list of analyst forecasts on Integral Diagnostics Ltd. stock, see the AU:IDX Stock Forecast page.
More about Integral Diagnostics Ltd.
Integral Diagnostics Limited is an Australian-listed company operating in the healthcare sector, providing diagnostic imaging services such as radiology across its network of medical facilities. The company serves hospitals, medical practitioners and patients, supporting clinical decision-making through imaging and related diagnostic solutions.
Average Trading Volume: 945,055
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$902.5M
For an in-depth examination of IDX stock, go to TipRanks’ Overview page.